Finance

Beta
Lists
RPRX:NASDAQ
Royalty Pharma plc
$55.87
+1.54%
(+0.85) 1D
$55.87
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RPRX...
Open
$55.27
High
$55.94
Low
$55.00
Mkt. cap
32.17B
Avg. vol.
4.09M
Volume
6.03M
Dividend
1.68%
Quarterly dividend
$0.24
Ex-dividend date
May 15, 2026
P/E ratio
29.27
52-wk high
$56.07
52-wk low
$33.37
EPS
$1.91
Beta
0.43
Shares outstanding
443.27M
No. of employees
100
Open
$55.27
High
$55.94
Low
$55.00
Mkt. cap
32.17B
Avg. vol.
4.09M
Volume
6.03M
Dividend
1.68%
Quarterly dividend
$0.24
Ex-dividend date
May 15, 2026
P/E ratio
29.27
52-wk high
$56.07
52-wk low
$33.37
EPS
$1.91
Beta
0.43
Shares outstanding
443.27M
No. of employees
100
Analyst outlook
Analyst Ratings
Based on 7 analysts giving stock ratings to RPRX in the past 3 months
Strong Buy
Buy
7
Hold
0
Sell
0
12 month forecast
Based on 7 Wall Street analysts offering 12 month price targets for RPRX in the last 3 months.
Highest
Current $55.87
$66.00 (+18.13%)
Average
$59.43 (+6.37%)
Lowest
$50.00 (-10.51%)
News stories
From sources across the web
About Royalty Pharma plc
CEO-
Employees100
Founded1996
Headquarters-
SectorPharmaceutical industry
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$1.30 / $1.18
+9.39%beat
Revenue / Est. (USD)
630.58M / 874.12M
-27.86%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
578.66M
609.29M
621.99M
630.58M
Cost of goods sold
-203.94M
12.14M
23.10M
-197.48M
Cost of revenue
-203.94M
12.14M
23.10M
-197.48M
Research and development expenses
300.50M
50.50M
50.50M
39.79M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
164.77M
117.73M
193.87M
159.49M
Operating expense
557.80M
169.00M
240.10M
195.58M
Total operating expenses
353.87M
181.14M
263.21M
-1.90M
Operating income
224.80M
428.16M
358.78M
632.48M
Other non operating income
-3.54M
2.42M
-9.17M
-2.20M
EBT including unusual items
90.64M
444.21M
355.91M
468.26M
EBT excluding unusual items
163.61M
373.87M
266.52M
564.54M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
30.18M
288.22M
214.20M
294.69M
Net profit margin
5.21%
47.30%
34.44%
46.73%
Earnings per share
1.14
1.17
1.47
1.30
Interest and investment income
8.33M
6.90M
7.07M
6.23M
Interest expense
-68.67M
-79.56M
-94.17M
-93.72M
Net interest expenses
-60.34M
-72.66M
-87.10M
-87.49M
Depreciation and amortization charges
-
-
-
-
EBITDA
225.49M
429.43M
359.98M
633.65M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more